Skip to main content
Livermore
Livermore
ZHEN

Acrivon Therapeutics, Inc.

ACRV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001781174

In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.

13F holders, Q1 2026

Institutional positions in Acrivon Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
44
−3 vs. Q4 2025
Shares held
16.2M
−1.68M (−9.4%) vs. Q4 2025
Total value
$22.6M
−$20.6M (−47.7%) vs. Q4 2025
New holders
10
11 more added
Sold out
13
11 more reduced

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ACRV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2026: 44 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 0 institutionsQ2 2022: 0 institutionsQ3 2022: 0 institutionsQ4 2022: 18 institutionsQ1 2023: 39 institutionsQ2 2023: 40 institutionsQ3 2023: 43 institutionsQ4 2023: 42 institutionsQ1 2024: 48 institutionsQ2 2024: 55 institutionsQ3 2024: 55 institutionsQ4 2024: 63 institutionsQ1 2025: 63 institutionsQ2 2025: 53 institutionsQ3 2025: 48 institutionsQ4 2025: 48 institutionsQ1 2026: 44 institutionsQ2 2026: 46 institutions
Value heldQ1 2026: $22.6M
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $0Q2 2022: $0Q3 2022: $0Q4 2022: $170.4MQ1 2023: $191.1MQ2 2023: $196.0MQ3 2023: $144.3MQ4 2023: $74.5MQ1 2024: $109.0MQ2 2024: $136.1MQ3 2024: $160.8MQ4 2024: $140.0MQ1 2025: $45.7MQ2 2025: $21.2MQ3 2025: $31.7MQ4 2025: $44.9MQ1 2026: $22.6MQ2 2026: $38.1M
Institutions holding ACRV and their total value by quarter
QuarterHoldersValue
Q2 202646$38.1M
Q1 202644$22.6M
Q4 202548$44.9M
Q3 202548$31.7M
Q2 202553$21.2M
Q1 202563$45.7M
Q4 202463$140.0M
Q3 202455$160.8M
Q2 202455$136.1M
Q1 202448$109.0M
Q4 202342$74.5M
Q3 202343$144.3M
Q2 202340$196.0M
Q1 202339$191.1M
Q4 202218$170.4M
Q3 20220$0
Q2 20220$0
Q1 20220$0
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q1 2026

Shares, value and share of portfolio for each institution holding Acrivon Therapeutics, Inc.; share changes are against Q4 2025.

Institutions holding ACRV in Q1 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Royal Bank of Canada25$00.00%−1,686−98.5%Reduced
Caitong International Asset Management Co., Ltd4$60.00%+4New
SBI Securities Co., Ltd.74$1030.00%00.0%Unchanged
Steward Partners Investment Advisory, LLC326$4530.00%+326New
Federation des caisses Desjardins du Quebec400$5560.00%00.0%Unchanged
Russell Investments Group, Ltd.481$6690.00%00.0%Unchanged
Redwood Park Advisors LLC500$6950.00%00.0%Unchanged
Nisa Investment Advisors, LLC584$8120.00%00.0%Unchanged
JPMorgan Chase & Co638$8230.00%−16,226−96.2%Reduced
BNP Paribas Arbitrage, SA634$8810.00%00.0%Unchanged
Wells Fargo & Company3,000$4.17K0.00%+3,000New
Vanguard Global Advisers, LLC4,453$6.19K0.00%+4,453New
Tower Research Capital LLC (TRC)4,526$6.29K0.00%+4,526New
Barclays PLC5,940$8.26K0.00%−18,462−75.7%Reduced
Federated Hermes, Inc.7,924$11.0K0.00%+2,312+41.2%Added
FMR LLC9,422$13.1K0.00%+800+9.3%Added
AAFCPAs Wealth Management, LLC10,678$14.8K0.01%00.0%Unchanged
Two Sigma Securities, LLC11,679$16.2K0.00%+11,679New
Goldman Sachs Group Inc14,742$20.5K0.00%−104,680−87.7%Reduced
Bank of America Corp16,513$23.0K0.00%−934−5.4%Reduced
Dimensional Fund Advisors LP18,364$25.4K0.00%00.0%Unchanged
Marex Group plc20,000$27.8K0.00%+10,000+100.0%Added
Prelude Capital Management, LLC24,015$33.4K0.00%−24,000−50.0%Reduced
Squarepoint Ops LLC27,472$38.2K0.00%+1,310+5.0%Added
Panagora Asset Management Inc33,814$47.0K0.00%+33,814New
UBS Group AG34,634$48.1K0.00%−313,907−90.1%Reduced
Morgan Stanley36,671$51.0K0.00%−10,160−21.7%Reduced
Northern Trust Corp48,902$68.0K0.00%−14,816−23.3%Reduced
XTX Topco Ltd66,882$93.0K0.00%+46,310+225.1%Added
State Street Corp67,145$93.3K0.00%00.0%Unchanged
Vanguard Fiduciary Trust Co107,529$149.5K0.00%+107,529New
Bridgeway Capital Management, LLC158,900$220.9K0.00%+116,000+270.4%Added
Gsa Capital Partners LLP186,716$260.0K0.02%+186,716New
BlackRock, Inc.208,939$290.4K0.00%+3,815+1.9%Added
Geode Capital Management, LLC236,391$328.7K0.00%+38,168+19.3%Added
Jane Street Group, LLC239,691$333.2K0.00%−102,380−29.9%Reduced
Two Sigma Investments, LP389,395$541.3K0.00%−195,674−33.4%Reduced
Marshall Wace, LLP560,436$779.0K0.00%+64,355+13.0%Added
Vanguard Capital Management LLC722,035$1.00M0.00%+722,035New
Renaissance Technologies LLC758,440$1.05M0.00%+124,271+19.6%Added
Acadian Asset Management LLC845,973$1.18M0.00%+264,765+45.6%Added
Wellington Management Group LLP888,130$1.23M0.00%00.0%Unchanged
Sands Capital Ventures, LLC2,122,605$2.95M0.70%00.0%Unchanged
Ra Capital Management, L.P.8,340,508$11.6M0.12%00.0%Unchanged
Citadel Advisors LLC0$00.00%−1,641,884−100.0%Sold out
Acorn Capital Advisors, LLC0$00.00%−405,237−100.0%Sold out
Two Sigma Advisers, LP0$00.00%−333,773−100.0%Sold out
Millennium Management LLC0$00.00%−121,524−100.0%Sold out
Baker Bros. Advisors LP0$00.00%−22,809−100.0%Sold out
Quadrature Capital Ltd0$00.00%−20,730−100.0%Sold out
Vermillion & White Wealth Management Group, LLC0$00.00%−18,100−100.0%Sold out
Schonfeld Strategic Advisors LLC0$00.00%−16,428−100.0%Sold out
Citigroup Inc0$00.00%−14,592−100.0%Sold out
Susquehanna International Group, LLP0$00.00%−12,433−100.0%Sold out
Point72 Asset Management, L.P.0$00.00%−10,876−100.0%Sold out
EverSource Wealth Advisors, LLC0$00.00%−373−100.0%Sold out
Optima Capital LLC0$00.00%−278−100.0%Sold out
Vanguard Group Inc––––Not filed